Literature DB >> 27431572

Overexpression of TP53 is associated with poor survival, but not with reduced response to hypomethylating agents in older patients with acute myeloid leukaemia.

Lieke H van der Helm1, Gerbrig Berger1, Arjan Diepstra2, Gerwin Huls1, Edo Vellenga1.   

Abstract

Entities:  

Keywords:  TP53 mutation; acute myeloid leukaemia; hypomethylating agents; older age; treatment

Mesh：

Substances：

Year:  2016        PMID： 27431572     DOI： 10.1111/bjh.14166

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  2 in total

1.  Ibrutinib added to 10-day decitabine for older patients with AML and higher risk MDS.

Authors:  Gerwin Huls; Dana A Chitu; Thomas Pabst; Saskia K Klein; Georg Stussi; Laimonas Griskevicius; Peter J M Valk; Jacqueline Cloos; Arjan A van de Loosdrecht; Dimitri Breems; Danielle van Lammeren-Venema; Isabelle van Zeventer; Rinske Boersma; Mojca Jongen-Lavrencic; Martin Fehr; Mels Hoogendoorn; Markus G Manz; Maaike Söhne; Rien van Marwijk Kooy; Dries Deeren; Marjolein W M van der Poel; Marie Cecile Legdeur; Lidwine Tick; Yves Chalandon; Emanuele Ammatuna; Sabine Blum; Bob Löwenberg; Gert J Ossenkoppele
Journal:  Blood Adv       Date:  2020-09-22

2.  Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia.

Authors:  Heiko Becker; Dietmar Pfeifer; Gabriele Ihorst; Milena Pantic; Julius Wehrle; Björn H Rüter; Lars Bullinger; Björn Hackanson; Ulrich Germing; Andrea Kuendgen; Uwe Platzbecker; Konstanze Döhner; Arnold Ganser; Anne Hagemeijer; Pierre W Wijermans; Hartmut Döhner; Justus Duyster; Michael Lübbert
Journal:  Ann Hematol       Date:  2020-06-06       Impact factor: 3.673
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.